Clinical trials: Blood Pressure, High
Hypertension With Overweight or Obesity
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;
- Trial name
- NCT07528027
- Testing
- HRS-7535
- Where
- 2 sites in China
- Volunteers
- 648 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Pulmonary Arterial Hypertension
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
The objectives of this study are to evaluate the efficacy and safety of sotatercept (MK-7962) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) at 24 weeks in…
- Trial name
- NCT04576988
- Testing
- Sotatercept, Background PAH Therapy
- Where
- 120 sites in United States, Argentina and 19 more
- Volunteers
- 324 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Open-angle Glaucoma
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost
Evaluation of the intraocular pressure (IOP) lowering effect of two iStent devices versus medical therapy in eyes of subjects with primary open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to medical…
- Trial name
- NCT01443988
- Testing
- iStent, Travoprost
- Where
- Armenia
- Volunteers
- 101 people
- Sponsor
- Glaukos Corporation
Hypertension
Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise
The aim of the observational study is to ascertain the degree of blood pressure control in the early-morning hours after 8 weeks of treatment with Telmisartan/Telmisartan+Hydrochlorothiazide and during 44 weeks of follow-up, in…
- Trial name
- NCT00946829
- Testing
- telmisartan
- Where
- 12 sites in Belgium, Canada and 10 more
- Volunteers
- 18,299 people
- Sponsor
- Boehringer Ingelheim
Erectile Dysfunction, Hypertension
Trial to Evaluate the Efficacy and Safety of HCP1302
Trial to Evaluate the Efficacy and Safety of HCP1302
- Trial name
- NCT02587988
- Testing
- HCP1302, HGP0904
- Volunteers
- 232 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension
The goal of this clinical study is to learn how effective and safe is a single administration of PA5346 Ocular Implant for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT06964061
- Testing
- PA5436 Ocular Implant, 115mcg
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- PolyActiva Pty Ltd
Glaucoma, Ocular Hypertension
A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)
Evaluate the effectiveness of dorzolamide-timolol (Cosopt®) as first line therapy in reducing intraocular pressure in patients with untreated Open angle glaucoma (OAG) or Ocular hypertension (OH).
- Trial name
- NCT00546286
- Testing
- dorzolamide hydrochloride (+) timolol maleate, Comparator: dorzolamide HCl/timolol maleate + prostaglandin
- Volunteers
- 170 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)
Evaluate the antihypertensive and neuroprotective effects of Hyzaar(R) in elderly subjects in comparison with Natrilix(TM).
- Trial name
- NCT00398541
- Testing
- losartan potassium (+) hydrochlorothiazide
- Volunteers
- 41 people
- Sponsor
- Organon and Co
Hypertension, Pulmonary
Efficacy and Safety of Ambrisentan in Children 8-18yrs
A 6-month (24-week), randomized, open label evaluation of the safety, tolerability, and efficacy of a high and low dose ambrisentan (adjusted for body weight) treatment group in subjects aged 8 years up to 18 years with pulmonary…
- Trial name
- NCT01332331
- Testing
- Ambrisentan - low dose, Ambrisentan - high dose
- Where
- 24 sites in United States, Argentina and 7 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Glaucoma
"First-in-human" Study To Assess the Safety and Tolerability of PBF-677 in Healthy Volunteers
The proposed trial a "Randomized, Double Blind, Placebo Controlled "first in-human" Study to Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-677 in Male Healthy Volunteers" (Protocol Code No:CUNFI-1509…
- Trial name
- NCT02639975
- Testing
- PBF-677
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL
Atrial Fibrillation, Hypertension
Validation Study of an Advanced Blood Pressure Monitor
The proposed clinical study aims to validate the effectiveness of the WPM04 blood pressure monitor developed by Withings as a diagnostic tool for cardiovascular disorders.
- Conditions
- Atrial Fibrillation, Hypertension, Valvular Heart Disease
- Trial name
- TALISMAN (NCT04030494)
- Testing
- BP measurement, AF detection, VHD detection
- Where
- France
- Volunteers
- 218 people
- Sponsor
- Withings
Hypertension
TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or Older
The aim of this study is to compare the effect of treatment with telmisartan on patients in whom the systolic BP is approximately 12 weeks after starting treatment under control for the first time between patients with isolated…
- Trial name
- TELSYS (NCT02242877)
- Testing
- Telmisartan, Telmisartan combined with hydrochlorothiazide
- Volunteers
- 3,320 people
- Sponsor
- Boehringer Ingelheim
Glaucoma, Ocular Hypertension
Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT
The purpose of the study is to compare the IOP lowering efficacy of Travoprost/Brinzolamide dosed daily in the morning or evening, vs TRAVATAN dosed once daily in the evening, and vs.
- Trial name
- NCT00767494
- Testing
- Travoprost/Brinzolamide fixed combination, Azopt, Travatan
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- Alcon Research
Hypertension
An Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes
To describe the effectiveness of angiotensin-converting enzyme inhibitor and non-dihydropyridine calcium channel blocker single pill combination on systolic blood pressure (SBP) lowering in hypertensive patients with elevated…
- Trial name
- HARVEST-TR (NCT02298556)
- Where
- 23 sites in Turkey (Türkiye)
- Volunteers
- 270 people
- Sponsor
- Abbott
Hypertension, Bradycardia
Novel Setup Algorithm for Cardiac Neuromodulation Therapy
After meeting all inclusion/exclusion criteria, subjects on standard pacing with the Moderato® or Moderato Plus Implantable Pulse Generator (IPG) will be subjected to two set-up sessions for the CNT algorithm: at week 4 and at…
- Trial name
- CS-10 (NCT05719454)
- Testing
- CNT testing
- Where
- 7 sites in Czechia, Hungary and 1 more
- Volunteers
- 30 people
- Sponsor
- BackBeat Medical Inc
Hypertension
Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled
To Evaluate the Efficacy of the Timing of the Administration of a Telmisartan/S-Amlodipine (Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy
- Trial name
- NCT02526875
- Testing
- Telminuvo®Tab. 40/2.5mg
- Where
- 10 sites in South Korea
- Volunteers
- 208 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension.
- Trial name
- OLMETREAT (NCT00311155)
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Where
- 79 sites in Austria, Belgium and 7 more
- Volunteers
- 694 people
- Sponsor
- Sankyo Pharma Gmbh
Albuminuria
Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria
Albumin in the urine is usually a signal that you might be at risk of cardiovascular complications. The purpose of this study is to determine if the albumin in your urine can be decreased by the treatment regimen that consists of…
- Trial name
- NCT00095290
- Testing
- Ramipril + Irbesartan
- Where
- 92 sites in United States, Australia and 12 more
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Glaucoma, Ocular Hypertension
6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination (Trav/Brinz) administered twice daily as compared to each of its marketed components (TRAVATAN Z® solution and AZOPT® suspension) and to the…
- Trial name
- NCT02140060
- Testing
- Dose Level A / Brinzolamide 1% ophthalmic suspension, Dose Level B / Brinzolamide 1% ophthalmic suspension, Dose Level C / Brinzolamide 1% ophthalmic suspension
- Volunteers
- 327 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%
The purpose of this study was to evaluate the safety and efficacy of a new ophthalmic suspension (Brinz/Brim) in lowering intraocular pressure (IOP) relative to its individual active components in subjects with open-angle…
- Trial name
- NCT01297920
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2%
- Volunteers
- 1,062 people
- Sponsor
- Alcon Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.